Lunresertib

DB19241InvestigationalSmall molecule

Lunresertib: Overview.

Mechanism: Pharmacologically active on Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
Curator reviewed
Formula / weight: C₁₈H₂₀N₄O₂ · 324.384 g/mol (avg)
Also known as: (1S)-2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl-1H-Pyrrolo[2,3-b]pyridine-3-carboxamide
Code names: RP-6306

Resolves to

Compound

Structure

InChIKeyARBRHWRTXPWZGN-UHFFFAOYSA-NSMILESCC1=C(C)N=C2N(C(N)=C(C(N)=O)C2=C1)C1=C(C)C=CC(O)=C1C

Targets

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lunresertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.